A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus

Antiviral Research

Volumn 90, Issue 1, 2011, Pages 1-8

  Goodchild, Sarah A ^a   O'Brien, Lyn M ^a   Steven, John ^b   Muller, Mischa R ^b   Lanning, Oliver J ^a   Logue, Christopher H ^a,c   D'Elia, Riccardo V ^a   Phillpotts, Robert J ^a   Perkins, Stuart D ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Humanisation; Immunotherapy; Monoclonal antibody; Venezuelan equine encephalitis virus

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1A3B 7; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; SEROLOGY; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C;

MUCAMBO VIRUS; MURINAE; MUS; VEEV COMPLEX; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 79953676838     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.01.010     Document Type: Article

References (44)

1. Abhinandan K.R., Martin A.C.R. Analyzing the " degree of humanness" of antibody sequences. J. Mol. Biol. 2007, 369:852-862.
2. Charles P.C., Walters E., Margolis F., Johnston R.E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 1995, 208:662-671.
3. Clark M., Cobbold S., Hale G., Waldmann H. Advantages of rat monoclonal antibodies. Immunol. Today 1983, 4:100-101.
4. Descotes J. Immunotoxicity of monoclonal antibodies. mAbs 2009, 1:104-111.
5. Druett H.A. A mobile form of the Henderson apparatus. J. Hyg. Camb. 1969, 67:437-448.
6. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 1992, 224:487-499.
7. Hawley R.J., Eitzen E.M. Biological weapons - a primer for microbiologists. Annu. Rev. Microbiol. 2001, 55:235-253.
8. Hilleman M.R. Overview: cause and prevention in biowarfare and bioterrorism. Vaccine 2002, 20:3055-3067.
9. Hu W.-G., Chau D., Wu J., Jager S., Nagata L. Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine 2007, 25:3210-3214.
10. Hu W.-G., Phelps A.L., Jager S., Chau D., Hu C.C., O'Brien L.M., Perkins S.D., Gates A.J., Phillpotts R.J., Nagata L.P. A recombinant humanised monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 2010, 28:5558-5564.
11. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol. 2006, 87:2467-2476.
12. Hunt A.R., Frederickson S., Maruyama T., Roehrig J.T., Blair C.D. The first human epitope map of the Alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutalizing activity. PLoS Neglect Trop. Dis. 2010, 13:e739.
13. Hunt A.R., Johnson A.J., Roehrig J.T. Synthetic peptides of Venezuelan equine encephalomyelitis virus E2 glycoprotein. I. Immunogenic analysis and identification of a protective peptide. Virology 1990, 179:701-711.
14. Hwang W.Y.K., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10.
15. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
16. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of Proteins of Immunological Interest 1991, U.S. Department of Health and Human Services, Bethesda, MD.
17. Kirsch M.I., Hulseweh B., Nacke C., Rulker T., Schirrmann T., Marschall H.-J., Hust M., Dubel S. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol. 2008, 8:66.
18. Kobayashi N., Söderlind E., Borrebaeck C.A. Analysis of assembly of synthetic antibody fragments: expression of functional scFv with predefined specificity. Biotechniques 1997, 23:500-503.
19. Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., Hammond P.W. A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol. 2007, 44:1986-1998.
20. Mathews J.H., Roehrig J.T., Trent D.W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encepalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J. Virol. 1985, 55:594-600.
21. May K.R. The Collison nebulizer: description, performance and application. Aerosol. Sci. 1973, 4:235-243.
22. O'Brien L. Inhibition of multiple strains of Venuzuelan equine encephalitis virus by a pool of four short interferening RNAs. Antivir. Res. 2007, 75:20-29.
23. O'Brien L.M., Underwood-Fowler C.D., Goodchild S.A., Phelps A.L., Phillpotts R.J. Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains. Virol. J. 2009, 6:206.
24. Pasquill F. The estimation of the dispersion of windborne material. Meteorol. Mag. 1961, 90:33-49.
25. Paessler S., Weaver S.C. Vaccines for Venezuelan equine encephalitis. Vaccine 2009, 27:D80-85.
26. Paessler S., Rijnbrand R., Stein D.A., Ni H., Yun N.E., Dziuba N., Borisevich V., Seregin A., Ma Y., Blouch R., Iversen P.L., Zacks M.A. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 2008, 376:357-370.
27. Phillpotts R. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res. 2006, 120:107-112.
28. Phillpotts R.J., Jones L.D., Howard S.C. Monoclonal antibody protects mice against infection and disease when given either before or up to 24h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 2002, 20:1497-1504.
29. Phillpotts R.J., O'Brien L., Appleton R.E., Carr S., Bennett A. Intranasal immunisation with defective Adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 2005, 23:1615-1623.
30. Reichert E., Clase A., Bacetty A., Larsen J. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur. Bioterror. 2009, 7:413-427.
31. Rico-Hesse R., Roehrig J.T., Dickerman R. Monoclonal antibodies define antigenic variation in the ID variety of Venezuelan equine encephalitis virus. Am. J. Trop. Med. Hyg. 1988, 38:187-194.
32. Rivas F., Diaz L.A., Cardenas V.M., Daza E., Bruzon L., Alcala A., De la Hoz O., Canceres F.M., Aristizabal G., Martinez J.W., Revelo D., De la Hoz F., Boshell J., Camacho T., Calderon L., Olano V.A., Villareal L.I., Roselli D., Alvarez G., Ludwig G., Tsai T. Epidemic Venezuelan equine encephalitis in La Guajira Colombia, 1995. J. Infect. Dis. 1997, 175:828-832.
33. Roehrig J.T., Bolin R.A. Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype I Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay. J. Clin. Microbiol. 1997, 35:1887-1890.
34. Roehrig J.T., Day J.W., Kinney R.M. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 1982, 118:269-278.
35. Roehrig J.T., Hunt A.R., Kinney R.M., Mathews J.H. In vitro mechanisms of monoclonal antibody neutralization of alphaviruses. Virology 1988, 165:66-73.
36. Roehrig J.T., Mathews J.H. The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 1985, 142:347-356.
37. Schroff R.W., Foon K.A., Beatty S.M., Oldham R.K., Morgan A.C. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985, 45:879-885.
38. Tabrizi M.A., Tseng C.-M.L., Roskos L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 2006, 11:81-88.
39. Tangri S., LiCalsi C., Sidney J., Sette A. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr. Med. Chem. 2002, 9:2191-2199.
40. Tangri S., Mothe B.R., Eisenbraun J., Sidney J., Southwood S., Briggs K., Zinckgraf J., Bilsel P., Newman M., Chesnut R., Licalsi C., Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 2005, 174:3187-3196.
41. Vogel P., Abplanalp D., Kell W., Ibrahim M.S., Downs M.B., Pratt W.D., Davis K.J. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch. Pathol. Lab. Med. 1996, 120:164-172.
42. Walton T.E., Alvarez O., Buckwater R.M., Johnson K.M. Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus. J. Infect. Dis. 1973, 137:227-237.
43. Wang E., Bowen R.A., Medina G., Powers A.M., Kang W., Chandler L.M., Shope R.E., Weaver S.C. Virulence and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype ID strains. Am. J. Trop. Med. Hyg. 2001, 65:64-69.
44. Weaver S.C., Ferro C., Barrera R., Boshell J., Navarro J.C. Venezuelan equine encephalitis. Ann. Rev. Entomol. 2004, 49:141-174.